Publicaties

2022

Smits FJ, Henry AC, Besselink MG, Busch OR, van Eijck CH, Arntz M, et al. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. Lancet 2022; Apr 28.

Schouten TJ, Daamen LA, Dorland G, van Roessel SR, Groot VP, Besselink MG, et al. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol 2022; Apr 25.

Schouten TJ, Daamen LA, Dorland G, van Roessel SR, Groot VP, Besselink MG, et al. ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol 2022 Apr 24. Online ahead of print.

de Jong EJM, Mommers I, Fariña Sarasqueta A, van der Geest LG, Heij L, de Hingh IHJT, et al. Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. Acta Oncol 2022 Apr 5;1-6. Online ahead of print.

Bootsma BT, Plat VD, van de Brug T, Huisman DE, Botti M, van den Boezem PB, et al. Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy: A nationwide analysis. Pancreatology 2022; Mar 10;S1424-3903(22)00095-3. Online ahead of print.

Pijnappel EN, Dijksterhuis WPM, Sprangers MAG, Augustinus S, de Vos-Geelen J, de Hingh IHJT, et al. The fear of cancer recurrence and progression in patients with pancreatic cancer. Support Care Cancer 2022; Feb 15. Online ahead of print.

de Jong EJM, van der Geest LG, Besselink MG, Bouwense SAW, Buijsen J, Dejong CHC, et al. Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. HPB (Oxford) 2022 Jan 23;S1365-182X(22)00044-2. Online ahead of print.

Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 2022, Jan 27; Online ahead of print.

Belkouz A, Van Roessel S, Strijker M, van Dam JL, Daamen L, van der Geest LG, et al. Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. Br J Cancer 2022, Jan 17. doi: 10.1038/s41416-021-01687-1.

2021

van Dongen JC, van der Geest LGM, de Meijer VE, van Santvoort HC, de Vos-Geelen J, Besselink MG, et al. Age and prognosis in patients with pancreatic cancer: a population-based study. Acta Oncol 2021 Dec 22;1-8.

de Jong EJM, Janssen QP, Simons TFA, Besselink MG, Bonsing BA, Bouwense SAW, et al. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Int J Cancer 2021 Dec 22. doi: 10.1002/ijc.33916.

van der Heijde N, Lof S, Busch OR, de Hingh I, de Kleine RH, Molenaar IQ, et al. Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy. Surgery 2021 Dec 11;S0039-6060(21)01145-4.

van Dam JL, Janssen QP, Besselink MG, Homs MYV, van Santvoort HC, van Tienhoven G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Eur J Cancer 2021 Nov 24;S0959-8049(21)01181-3.

Zwart MJW, Jones LR, Fuente I, Balduzzi A, Takagi K, Novak S, et al. Performance with robotic surgery versus 3D- and 2D-laparoscopy during pancreatic and biliary anastomoses in a biotissue model: pooled analysis of two randomized trials. Surg Endosc 2021 Nov 19. doi: 10.1007/s00464-021-08805-3.

Groen JV, Michiels N, van Roessel S, Besselink MG, Bosscha K, Busch OR, et al. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Br J Surg 2021 Nov 17;znab345.

Groen JV, Smits FJ, Molenaar IQ, Bonsing BA, van Santvoort HC, Mieog JSD; Dutch Pancreatic Cancer Group. Pancreas-preserving surgical interventions during relaparotomy for pancreatic fistula after pancreatoduodenectomy. HPB (Oxford) 2021 Oct 23;S1365-182X(21)01661-0.

Daamen LA, Dorland G, Brada LJH, Groot VP, van Oosten AF, Besselink MG, et al. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. HPB (Oxford) 2021 Sep 24;S1365-182X(21)01624-5.

Mackay TM, Dijksterhuis WPM, Latenstein AEJ, van der Geest LG, Sprangers MAG, van Eijck CHJ, et al. The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. HPB (Oxford) 2021 Sep 25;S1365-182X(21)01623-3.

Groen JV, Smits FJ, Koole D, Besselink MG, Busch OR, den Dulk M, et al. Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy: a multicentre cohort study and meta-analysis. Br J Surg 2021 Oct 5;znab273.

van Roessel S, Soer EC, Daamen LA, van Dalen D, Fariña Sarasqueta A, Stommel MWJ, et al. Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. Eur J Surg Oncol 2021 Oct;47(10):2525-2532.

Pijnappel EN, Dijksterhuis WPM, van der Geest LG, de Vos-Geelen J, de Groot JWB, Homs MYV, et al. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. J Natl Compr Canc Netw 2021 Aug 27;1-8. doi: 10.6004/jnccn.2021.7028. Online ahead of print.

Petrova E, Suurmeijer JA, Mackay TM, Bolm L, Lapshyn H, Honselmann KC, et al. Outcome of pancreatic anastomoses during pancreatoduodenectomy in two national audits. Surgery 2021 Aug 6;S0039-6060(21)00663-2.

Rijken A, Bakkers C, van Erning FN, van der Geest LG, de Vos-Geelen J, Besselink MG, et al. Incidence, Treatment, and Survival of Synchronous Peritoneal Metastases in Pancreatic Cancer: Update of a Nationwide Cohort. Pancreas 2021 Aug 3. Online ahead of print.

Brada LJH, Daamen LA, Magermans LG, Walma MS, Latifi D, van Dam RM, et al. Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer Following Upfront FOLFIRINOX versus FOLFIRINOX Only: Multicenter Propensity Score-Matched Analysis. Ann Surg 2021, Jul 29.

Brada LJH, Walma MS, Daamen LA, van Roessel S, van Dam RM, de Hingh IH, et al. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. J Surg Oncol 2021 Jun 11. doi: 10.1002/jso.26567.

Strijker M, van der Sijde F, Suker M, Boermeester MA, Bonsing BA, Bruno MJ, et al. Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. PB (Oxford) 2021 May 19;S1365-182X(21)00140-4.

Latenstein AEJ, Blonk L, Tjahjadi NS, de Jong N, Busch OR, de Hingh IHJT, et al. Long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery: a multicenter, cross-sectional study. HPB (Oxford) 2021 Apr 28;S1365-182X(21)00112-X.

Walma MS, Rombouts SJ, Brada LJH, Borel Rinkes IH, Bosscha K, Bruijnen RC, et al. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials 2021; Apr 29;22(1):313.

Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021 Mar 23;21(1):300.

van Roessel S, Soer EC, Daamen LA, van Dalen D, Fariña Sarasqueta A, Stommel, et al. Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. Eur J Surg Oncol. 2021 Mar 15. Online ahead of print.

Latenstein AEJ, Mackay TM, van der Geest LGM, van Eijck CHJ, de Meijer VE, Stommel MWJ, et al. Effect of centralization and regionalization of pancreatic surgery on resection rates and survival. Br J Surg. 2021 Mar 19. Online ahead of print.

de Jong EJ, Geurts SM, van der Geest LG, Besselink MG, Bouwense SA, Buijsen J, et al. A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. Eur J Surg Oncol 2021 Mar 6. Online ahead of print.

Strijker M, van Veldhuisen E, van der Geest LG, Busch OR, Bijlsma MF, Haj Mohammad N, et al. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Biomarkers. 2021 Mar 5:1-15. Online ahead of print.

van Roessel S, Soer EC, van Dieren S, Koens L, van Velthuysen MLF, Doukas M, et al. Axial slicing versus bivalving in the pathological examination of pancreatoduodenectomy specimens (APOLLO): a multicentre randomized controlled trial. HPB (Oxford) 2021 Jan 21;S1365-182X(21). Online ahead of print.

Zwart MJW, Nota CLM, de Rooij T, van Hilst J, Te Riele WW, van Santvoort HC, Hagendoorn J, et al. Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3). Ann Surg. 2021 Feb 1. Online ahead of print.

Nicholas E, van Roessel S, de Burlet K, Hore T, Besselink MG, Connor S. Using Textbook Outcomes to benchmark practice in pancreatic surgery. ANZ J Surg. Online ahead of print.

Daamen LA, van Goor IWJM, Schouten TJ, Dorland G, van Roessel SR, Besselink MG, et al. Microscopic resection margin status in pancreatic ductal adenocarcinoma – A nationwide analysis. Eur J Surg Oncol 2020 Dec 2; S0748-7983(20)31041-6. Online ahead of print.

2020

Brada LJH, Walma MS, van Dam RM, de Vos-Geelen J, de Hingh IH, Creemers GJ, et al. The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. Pancreatology 2020 Dec 3; S1424-3903(20)30845-0. Online ahead of print.

Pranger BK, van Dam JL, Groen JV, van Eijck CH, Koerkamp BG, Bonsing BA, et al. Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications. HPB (Oxford). 2020 Dec 3; S1365-182X(20)31247-8. Online ahead of print.

Walma MS, Brada LJ, Patuleia SIS, Blomjous JG, Bollen TL, Bosscha K, et al. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Eur J Surg Oncol. 2020 Nov 26; S0748-7983(20)31033-7. Online ahead of print.

Versteijne E, Suker M, Groen JV, Besselink MG, Bonsing BA, Bosscha K, et al. Dutch Pancreatic Cancer Group. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible But Non-Randomized Patients. Ann Surg. 2020. Online ahead of print.

Van Dongen JC, Suker M, Versteijne E, Bonsing BA, Mieog JSD, de Vos-Geelen J, et al. Dutch Pancreatic Cancer Group. Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). Ann Surg. 2020 Nov 12. Online ahead of print.

Latenstein AEJ, Dijksterhuis WPM, Mackay TM, Beijer S, van Eijck CHJ, de Hingh IHJT, et al. Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. Cancer Med 2020 Oct 27; Online ahead of print.

Mackay TM, Latenstein AEJ, Sprangers MAG, van der Geest LG, Creemers GJ, van Dieren S, et al. Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. J Natl Compr Canc Netw 2020 Oct 1;18(10):1354-1363.

Steen MW, van Rijssen LB, Festen S, Busch OR, Groot Koerkamp B, van der Geest LG, et al. Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes. BJS Open. 2020 Aug 25.

Scholten L, Latenstein AE, Aalfs CM, Bruno MJ, Busch OR, Bonsing BA, et al. Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. United European Gastroenterol J. 2020 Jul 23

Latenstein AE, Mackay TM, van Huijgevoort NC, Bonsing BA, Bosscha B, Hol L, et al. Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer. HPB (Oxford) 2020 Jul 16;S1365-182X(20)31056-X.

Daamen LA, Groot VP, Besselink MG, Bosscha K, Busch OR, Cirkel GA, et al. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Ann Surg. 2020 Jul 8. Online ahead of print.

Zwart MJW, Jones LR, Balduzzi A, Takagi K, Vanlander A, van den Boezem PB, et al. Added value of 3D-vision during robotic pancreatoduodenectomy anastomoses in biotissue (LAEBOT 3D2D): a randomized controlled cross-over trial. Surg Endosc. 2020 Jul 13. Online ahead of print.

Smits FJ, Verweij ME, Daamen LA, van Werkhoven CH, Goense L, Besselink MG, et al. Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission: Analysis of a Nationwide Audit. Ann Surg 2020 Jun 3. Online ahead of print.

Mackay T, LB van Rijssen, JO Andriessen, M Suker, et al. Patient satisfaction and quality of life before and after treatment of pancreatic and periampullary cancer: a prospective multicenter study. J Natl Compr Netw. 2020 Jun;18(6):704-711.

Latenstein A, Mackay T, Creemers, GJ, van Eijck CH, de Groot JW, Mohammad NH, et al. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncol. 2020 Jun.

Groen JV, Douwes TA, van Eycken E, van der Geest LGM, Johannesen TB, Besselink MG, et al. Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. Ann Surg Oncol 2020 May 9. Online ahead of print.

Smits FJ, Henry AC, van Eijck CH, Besselink MG, Busch OR, Arntz M, et al. Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial. Trials 2020 May 7;21(1):389.

Moekotte AL, Malleo G, van Roessel S, Bonds M, Halimi A, Zarantonello L, Napoli N, et al. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg. 2020 Apr 7. [Epub ahead of print]

Mackay TM, Smits FJ, Latenstein AEJ, Bogte A, Bonsing BA, Bos H, et al. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial. Trials. 2020 Apr 16;21(1):334.

Stoop TF, Scholten L, Besselink MG; Dutch Pancreatic Cancer Group. Author response to: Comment on: Systematic review of functional outcome and quality of life after total pancreatectomy. Br J Surg. 2020 Apr;107(5):618.

Strijker M, Mackay TM, Bonsing BA, Bruno MJ, van Eijck CHJ, de Hingh IHJT, Koerkamp BG, van Laarhoven HW, et al. Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Ann Surg. 2020 Apr;271(4):e102-e104. No abstract available.

Overbeek KA, Cahen DL, Kamps A, Konings ICAW, Harinck F, Kuenen MA, Koerkamp BG, Besselink MG, van Eijck CH, et al. Dutch Familial Pancreatic Cancer Surveillance Study Group. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Fam Cancer. 2020 Mar 19. doi: 10.1007/s10689-020-00171-8. [Epub ahead of print]

Van Dongen JC, Smits FJ, van Santvoort HC, Molenaar IQ, Busch OR, Besselink MG, Aziz MH, Groot Koerkamp B, van Eijck CHJ; Dutch Pancreatic Cancer Group. C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. HPB (Oxford). 2020 Mar 11. pii: S1365-182X(20)30055-1. doi: 10.1016/j.hpb.2020.02.005. [Epub ahead of print] 

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Of download deze publicatie als PDF. J Clin Oncol. 2020 Feb 27:JCO1902274. doi: 10.1200/JCO.19.02274. [Epub ahead of print].

Latenstein AEJ, van Roessel S, van der Geest LGM, Bonsing BA, Dejong CHC, Groot Koerkamp B, de Hingh IHJT, et al. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Ann Surg Oncol. 2020 Feb 12. doi: 10.1245/s10434-020-08235-w.

2019

Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2019 Dec 13;125:83-93.

Scholten L, Latenstein AEJ, van Eijck C, Erdmann J, et al. Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. Surgery. 2019;166(6):1017-1026.

Scholten L, Stoop TF, Del Chiaro M, Busch OR, et al. Systematic review of functional outcome and quality of life after total pancreatectomy. Br J Surg. 2019;106(13):1735-1746.

Klompmaker S, de Rooij T, Koerkamp BG, Shankar AH, et al. International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy. Ann Surg. 2019 Oct 17. [Epub ahead of print]

Linnemann RJA, Patijn GA, van Rijssen LB, Besselink MG, et al. The role of abdominal drainage in pancreatic resection – A multicenter validation study for early drain removal. Pancreatology. 2019;19(6):888-896.

Dijkgraaf MG, van Hilst J, Bossuyt PM, Besselink MG. The harms of early cessation of trials on systematic reviews – Authors’ reply. Lancet Gastroenterol Hepatol. 2019;4(9):667-668.

Mackay TM, Smits FJ, Roos D, Bonsing BA, et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB (Oxford). 2019 Aug 19. pii: S1365-182X(19)30610-0.

Huang L, Jansen L, Balavarca Y, van der Geest L, et al. Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study. Ann Surg. 2019 Aug 13. doi: 10.1097/SLA.0000000000003558. [Epub ahead of print].

Smits FJ, Molenaar IQ, Besselink MG, Borel Rinkes IHM, et al. Early recognition of clinically relevant postoperative pancreatic fistula: a systematic review. HPB (Oxford). 2019 S1365-182X(19)30619-7.

Van Veldhuisen E, van den Oord C, Brada LJ, Walma MS, et al. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers (Basel). 2019 Jul 12;11(7).

Smits FJ, van Santvoort HC, Besselink MG, Boerma D, et al. Predicting Successful Catheter Drainage in Patients With Pancreatic Fistula After Pancreatoduodenectomy. Pancreas. 2019;48(6):811-816.

Strijker M, Belkouz A, van der Geest LG, et al. Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol. 2019;58(7):1048-1055.

van Roessel S, Mackay TM, van Dieren S, van der Schelling, et al. Textbook Outcome: Nationwide Analysis of a Novel Quality Measure in Pancreatic Surgery. Ann Surg. 2019 Jul 3. doi: 10.1097/SLA.0000000000003451. [Epub ahead of print]

Mackay TM, Wellner UF, van Rijssen LB, Stoop TF, et al. Variation in pancreatoduodenectomy as delivered in two national audits. Br J Surg. 2019;106(6):747-755.

Mackay TM, van Erning FN, van der Geest LGM, de Groot JWB, et al. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. Eur J Cancer. 2019;106:99-105.

Van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4(3):199-207.

2018

Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, van Eijck CHJ, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946-958.

Zijlstra M, van der Geest LGM, van Laarhoven HWM, et al. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta Oncol. 2018;57(9):1185-1191.

Van Erning FN, Mackay TM, van der Geest LGM, Groot Koerkamp B, et al. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol. 2018;57(12):1655-1662.

Daamen LA, Smits FJ, Besselink MG, Borel Rinkes IH, et al. Dutch Pancreatic Cancer Group. A web-based overview, systematic review and meta-analysis of pancreatic anastomosis techniques following pancreatoduodenectomy. HPB (Oxford). 2018 May. doi:10.1010/j.hpb.2018.03.003.

Strijker M, Gerritsen A, van Hilst J, et al. The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and Periampullary Diseases. Pancreas. 2018;47(4):495-501.

Van Rijssen LB, Zwart MJ, Van Dieren S, et al. Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. HPB (Oxford). 2018 Mar 20. pii: S1365-182X(18)30729-9.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, et al. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol. 2018;57(2):195-202.

de Rooij T, van Hilst J, Bosscha K, et al. Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. Trials. 2018;3;19(1):1.

2017

Mungroop TH, van Rijssen LB, van Klaveren D, Smits FJ, et al. Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External Validation. Ann Surg. 2017 Dec 12. doi: 10.1097 & online calculator.

Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, Busch OR, van Santvoort HC, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Current Strategies for Detection and Treatment of Recurrence of Pancreatic Ductal Adenocarcinoma After Resection: A Nationwide Survey. HPB (Oxford). 2018 May. doi:10.1010/j.hpb.2018.03.003.

van der Geest LGM, Lemmens VEPP, de Hingh IHJT, van Laarhoven CJHM, Bollen TL, Nio CY, van Eijck CHJ, Busch ORC, Besselink MG; Dutch Pancreatic Cancer Group. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017 Oct;104(11):1568-1577.

van der Geest LGM, Haj Mohammad N, Besselink MGH, Lemmens VEPP, Portielje JEA, van Laarhoven HWM, Wilmink JHW; Dutch Pancreatic Cancer Group. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Med. 2017 Oct 16.

van Rijssen LB, Koerkamp BG, Zwart MJ, Bonsing BA, Bosscha K, van Dam RM, et al.Dutch Pancreatic Cancer Group. Nationwide prospective audit of pancreatic surgery: design,accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. HPB (Oxford). 2017 Oct;19(10):919-926.

de Rooij T, van Hilst J, Topal B, Bosscha K, Brinkman DJ, Gerhards MF, de Hingh IH, Karsten TM, Lips DJ, Luyer MD, Marsman HA, van Rijssen LB, Steen MW, Busch OR, Festen S, Besselink MG; Dutch Pancreatic Cancer Group. Outcomes of a Multicenter Training Program in Laparoscopic Pancreatoduodenectomy (LAELAPS-2). Ann Surg. 2017 Nov 2.

Nota CL, Zwart MJ, Fong Y, Hagendoorn J, Hogg ME, Koerkamp BG, Besselink MG, Molenaar IQ; Dutch Pancreatic Cancer Group. Developing a robotic pancreas program: the Dutch experience. J Vis Surg. 2017 Aug 21.

Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the DutchPancreatic Cancer Audit. van Rijssen LB, Koerkamp BG, Zwart MJ, Bonsing BA, Bosscha K, van Dam RM, van Eijck CH, Gerhards MF, van der Harst E, de Hingh IH, de Jong KP, Kazemier G, Klaase J, van Laarhoven CJ, Molenaar IQ, Patijn GA, Rupert CG, van Santvoort HC, Scheepers JJ, van der Schelling GP, Busch OR, Besselink MG for theDutch Pancreatic Cancer Group. HPB (Oxford) 2017.

Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. van der Geest LGM, Lemmens VEPP, de Hingh IHJT, van Laarhoven CJHM, Bollen TL, Nio CY, van Eijck CHJ, Busch ORC, Besselink MG for the Dutch Pancreatic Cancer Group. Br J Surg. 2017 Oct;104(11):1568-1577

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, et al. for the Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group. Acta Oncol. 2017.

2016

2015

 2014

2012

2011

Back To Top